Skip to main content
Erschienen in: Clinical and Translational Oncology 6/2014

01.06.2014 | Research Article

Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

verfasst von: L. Wang, X. Huang, X. Zheng, X. Wang, S. Li, L. Zhang, Z. Yang

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Concurrent chemoradiotherapy (CCRT) has been widely used during the past decades in clinical trials and has now become a common treatment option in many clinical settings. The present study was designed to evaluate the efficacy of combining radiation with low-dose docetaxel in DU-145 prostate cancer xenograft models.

Methods

Male BALB/c nude mice bearing human DU-145 prostate tumors were assigned to four treatment groups: (1) control, (2) docetaxel (10 mg/kg/week, i.v., ×3 weeks), (3) radiation (2 Gy, q.d. ×5, ×3 weeks), (4) CCRT (the combination of docetaxel and radiation). Treatment efficacy was determined by tumor volume and tumor regression measurements. The extent of apoptosis in tumors in response to treatments was assessed via terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay. In addition, immunohistochemical staining of CD34 was done to quantify microvessel density in the tumors.

Results

Our in vivo studies using DU-145 xenograft models in nude mice showed that CCRT compared to either alone significantly inhibited tumor growth, and the percentages of tumor regression were 32.6, 44.2, and 68.6 % for docetaxel, radiation, and CCRT, respectively. Moreover, CCRT did not significantly affected mice weight as compared to docetaxel or radiation alone. TUNEL assays showed that significantly more apoptotic cells were induced in the tumors treated with CCRT than either treatment alone. Anti-CD34 immunohistochemical staining indicated that CCRT significantly inhibited tumor angiogenesis.

Conclusion

These findings suggest that CCRT with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts, by enhancing apoptosis and suppressing angiogenesis. Based on these preclinical findings, we suggest that CCRT for the treatment of prostate cancer deserves further development.
Literatur
1.
2.
Zurück zum Zitat Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10:1081–7. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10:1081–7.
3.
Zurück zum Zitat Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Cancer Netw. 2013;11:183–7. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Cancer Netw. 2013;11:183–7.
4.
Zurück zum Zitat Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18.PubMedCrossRef Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18.PubMedCrossRef
5.
Zurück zum Zitat Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;19:3500–5.PubMed Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;19:3500–5.PubMed
6.
Zurück zum Zitat Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130–5.PubMedCrossRef Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130–5.PubMedCrossRef
7.
Zurück zum Zitat Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.PubMedCrossRef Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.PubMedCrossRef
8.
Zurück zum Zitat Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842–50.PubMed Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842–50.PubMed
9.
Zurück zum Zitat Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;3:2431–8.PubMed Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;3:2431–8.PubMed
10.
Zurück zum Zitat Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.PubMedCrossRef Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.PubMedCrossRef
11.
Zurück zum Zitat Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.PubMedCrossRef Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.PubMedCrossRef
12.
Zurück zum Zitat Kumar P, Perrotti M, Weiss R, Todd M, Goodin S, Cummings K, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22:1909–15.PubMedCrossRef Kumar P, Perrotti M, Weiss R, Todd M, Goodin S, Cummings K, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22:1909–15.PubMedCrossRef
13.
Zurück zum Zitat Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 2008;270:229–33.PubMedCrossRef Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 2008;270:229–33.PubMedCrossRef
14.
Zurück zum Zitat Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, et al. (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 2005;4:197–205.PubMedCrossRef Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, et al. (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 2005;4:197–205.PubMedCrossRef
15.
Zurück zum Zitat Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol. 2007;4:86–100.PubMedCrossRef Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol. 2007;4:86–100.PubMedCrossRef
16.
Zurück zum Zitat Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high-risk prostate cancer. Rev Recent Clin Trials. 2011;6:64–8.PubMedCrossRef Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high-risk prostate cancer. Rev Recent Clin Trials. 2011;6:64–8.PubMedCrossRef
17.
Zurück zum Zitat Milas L. Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer. 2002;3(Suppl 2):S29–36.PubMedCrossRef Milas L. Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer. 2002;3(Suppl 2):S29–36.PubMedCrossRef
18.
Zurück zum Zitat Perrotti M, Doyle T, Kumar P, McLeod D, Badger W, Prater S, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol. 2008;26:276–80.PubMedCrossRef Perrotti M, Doyle T, Kumar P, McLeod D, Badger W, Prater S, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol. 2008;26:276–80.PubMedCrossRef
19.
Zurück zum Zitat Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, et al. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. BJU Int. 2012;110:E721–6.PubMedCrossRef Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, et al. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. BJU Int. 2012;110:E721–6.PubMedCrossRef
20.
Zurück zum Zitat Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (taxotere): summary of clinical data. Semin Oncol. 1999;26:19–24.PubMed Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (taxotere): summary of clinical data. Semin Oncol. 1999;26:19–24.PubMed
21.
Zurück zum Zitat Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist. 2004;9:538–45.PubMedCrossRef Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist. 2004;9:538–45.PubMedCrossRef
22.
Zurück zum Zitat Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11–8.PubMedCrossRef Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11–8.PubMedCrossRef
23.
Zurück zum Zitat Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–72.PubMed Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–72.PubMed
24.
Zurück zum Zitat Ahmad M, Khurana NR, Jaberi JE. Ionizing radiation decreases capillary-like structure formation by endothelial cells in vitro. Microvasc Res. 2007;73:14–9.PubMedCrossRef Ahmad M, Khurana NR, Jaberi JE. Ionizing radiation decreases capillary-like structure formation by endothelial cells in vitro. Microvasc Res. 2007;73:14–9.PubMedCrossRef
25.
Zurück zum Zitat Tsai JH, Makonnen S, Feldman M, Sehgal CM, Maity A, Lee WM. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther. 2005;4:1395–400.PubMedCrossRef Tsai JH, Makonnen S, Feldman M, Sehgal CM, Maity A, Lee WM. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther. 2005;4:1395–400.PubMedCrossRef
26.
Zurück zum Zitat Lorke DE, Wenzel S, Siebert K, Zywietz F. Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 1999;44:895–904.PubMedCrossRef Lorke DE, Wenzel S, Siebert K, Zywietz F. Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 1999;44:895–904.PubMedCrossRef
Metadaten
Titel
Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
verfasst von
L. Wang
X. Huang
X. Zheng
X. Wang
S. Li
L. Zhang
Z. Yang
Publikationsdatum
01.06.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1120-3

Weitere Artikel der Ausgabe 6/2014

Clinical and Translational Oncology 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.